India's largest pharmaceutical comI pay, Sun Pharmaceutical consolidated net profit of ₹2,654.6 crore for the fourth quarter (Q4) of 2023-24 (FY24), up 33.7 per cent from ₹1,984.5 crore. The company's gross sales grew by 10 per cent to ₹11,813.3 crore.
The board has proposed a final dividend of 5 per share for FY24, in addition to the interim dividend of ₹8.5 per share, bringing the total dividend for FY24 to 13.5 per share, compared to ₹11.5 per share for 2022-23 (FY23).
The board of directors also approved the appointment of Dilip Shanghvi, managing director of the company, as chairman of the board with immediate effect. Sun Pharma's stock ended the day's trade on BSE at 1,540.3, down marginally. The adjusted net profit (excluding exceptional items) for Q4FY24 was €2,756.2 crore, up 27.8 per cent year-on-year.
our businesses surpassed $1 billion in annual sales, namely global specialty and emerging markets (EMS). This achievement of critical mass in key markets is a testimony to several years of hard work put in by respective teams.
This story is from the May 23, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the May 23, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Indian sports beyond the boundary
Little has been written about Indian sport, and practically nothing about the governance challenges as sport is powered by commerce.
Expansion of Ayushman Bharat a priority
Expansion of Ayushman Bharat Yojana to cover everyone aged above 70 years, launch of the National Health Claims Exchange (NHCX) and a special drive against tobacco use among youngsters were among the top agenda items discussed during the first high-level meeting chaired by Union Minister of Health and Family Welfare, JP Nadda on Friday.
MAKING A RACQUET
At long last, India has a player in the top 100 ATP rankings. But can Indian tennis match the success of badminton?
Will rural consumers roar?
\"Rural FMCG growth overtakes urban after 5 quarters,\" read the headline (Business Standard, May 8, 2024).
MFS or NPS? Go for both if you don't mind latter's lock-in
If one were to compare the category average returns of Tier-I equity plans of the National Pension System (NPS) with the direct plans of largecap mutual funds (MFS), the latter have a small edge currently.
Ambuja eyes more buys after Penna deal
Adani Group aims to become leader in cement sector in 4 years
Sensex, Nifty hit lifetime highs
Benchmark equity indices Sensex and Nifty hit their new closing lifetime highs on Friday, following buying in market heavyweights HDFC Bank, Reliance Industries and Mahindra & Mahindra amid encouraging export data.
Short-term margin overhang likely for Tata Communications
The management of Tata Communications presented its product-to-platform strategy and explained how it hopes to grow its new products and portfolios, and geographies.
CLSA sees further rerating scope in Vedanta
Shares of Vedanta rose as much as 2.8 per cent on Friday after the Hong Kong-based brokerage CLSA in a report said there was scope for further re-rating for the stock.
Abrdn favours Chinese, Indian stocks on policy boost hopes
Abrdn Plc prefers Chinese and Indian stocks over their Japanese peers in the next three to six months, betting that the right policy moves would help the two emerging markets lure fund inflows.
